中国科大发明抗肿瘤微型“纳米航母”
安徽省科技厅 · 2016/04/14
中国科学技术大学生命科学学院和医学中心王均教授课题组与美国Emory大学聂书明教授课题组合作,发明了一种微型“纳米航母”药物递送体系。


中国科大王均教授课题组日前与美国埃默里大学聂书明教授课题组合作,发明了一种微型“纳米航母”药物递送体系,实现更加精准有效的抗肿瘤药物递送。研究成果发表在最新一期著名期刊《美国科学院院刊》上。

纳米药物递送系统,在将具有活性的药物分子递送到肿瘤细胞的过程中,面临着复杂的生物环境和多重生物屏障。小分子化疗药物或小尺寸药物载体(小于10纳米),在血液循环中容易被肾脏过滤快速清除;合适尺寸和表面特性的药物载体(如100纳米)能延长药物血液循环,并有效地从肿瘤病理状态下不完整的血管中溢出,但难以扩散到整个肿瘤组织,无法有效接触肿瘤细胞,导致药物递送的失败。

王均教授课题组与聂书明教授课题组利用一个较大尺度的纳米载体(约90纳米)运载多个小尺度纳米载体(约5纳米),并将药物携带在小尺度载体上,形成复合的多级药物输送体系。在其进入血液后,复合结构的纳米载体能够延长药物在血液中的循环时间,并从肿瘤血管中溢出,进入到肿瘤组织。紧接着连接大-小尺度载体的化学键断裂,释放出小尺度载体进一步扩散到整个肿瘤组织,有效地将抗癌药物输送到肿瘤细胞。这种微型“纳米航母”药物递送体系,改变了过去抗肿瘤药物递送所存在的技术难点,实现了更加精准有效的抗肿瘤药物递送。

所有文章仅代表作者观点,不代表本站立场。如若转载请联系原作者。
查看更多
  • Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy

    Successively overcoming a series of biological barriers that cancer nanotherapeutics would encounter upon intravenous administration is required for achieving positive treatment outcomes. A hurdle to this goal is the inherently unfavorable tumor penetration of nanoparticles due to their relatively large sizes. We developed a stimuli-responsive clustered nanoparticle (iCluster) and justified that its adaptive alterations of physicochemical properties (e.g. size, zeta potential, and drug release rate) in accordance with the endogenous stimuli of the tumor microenvironment made possible the ultimate overcoming of these barriers, especially the bottleneck of tumor penetration. Results in varying intractable tumor models demonstrated significantly improved antitumor efficacy of iCluster than its control groups, demonstrating that overcoming these delivery barriers can be achieved by innovative nanoparticle design.

    展开 收起
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test